The
Biomarker Summit 2018, to be held on March 27-28, 2018 in San Diego, CA at the Omni San Diego Hotel, is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization.
Topics to be covered:
A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector.
Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments in four major therapeutic areas, formally organized in the following tracks:
Joint Plenary Sessions:
- Opening Keynote Session - Historical Perspective & Current State of the Industry
- Round Table Discussions
- Lunch Session: Big Data Analytics & Bioinformatics for Biomarkers Development
- Award Ceremony & Closing Keynote Session - Predictions for future
Oncology Biomarkers- Immuno-Oncology Biomarkers
- Circulating Tumor Cells, Microvesicles, DNA and RNA
Neurological Biomarkers- Biomarkers for Early Identification of Neurological Disease
- Monitoring Progression and Treatment Efficacy using Biomarkers
Inflammatory & Immunological Biomarkers- Biomarkers for Early Progressive Inflammatory & Immunological Diseases
- Biomarkers as Surrogate Endpoints for Clinical Trials
Cardiovascular Biomarkers- Biomarkers for Heart Failure & Acute Coronary Syndrome
- Biomarkers for Metabolic Syndrome & Cardiovascular Risk
We hope to see you there!
PLENARY KEYNOTE SPEAKERS
- Bruce W.M. Jordan, Vice President, International Business Leader, Personalised Healthcare Solutions (PHCS), Centralised and Point of Care Solutions, Roche Diagnostics
- Douglas Galasko, Professor of Neurosciences, UCSD
- William (Frank) Peacock, Professor, Emergency Medicine, Baylor College of Medicine
- Nathan Price, ISB Associate Director and Professor, Institute for Systems Biology
PLENARY SPEAKERS
- TBA (To Be Announced), CGI
- Gary Gustavsen, Vice President, Health Advances
- Thomas Kleen, Vice President, Immune Monitoring and Specialty Lab Services, Precision For Medicine
- Parag Mallick, Assistant Professor, Canary Center for Cancer Early Detect, Stanford University
- John Schilling, Director & Advisor of Diagnostics, Eli Lilly
- Cristina Stefan, Global Clinical Leader, Oncology Diagnostics, Roche
- Lorenzo Trippa, Associate Professor, Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School
Oncology Biomarkers - DISTINGUISHED SPEAKERS
- Jaffer Ajani, Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center
- Cedric Dos Santos, Sr Scientist | Heme/Onc Clinical Biomarkers, Amgen
- Michael Heller, Professor, University of California, San Diego
- Louis Levy, Director Corporate & Business Development, Ultivue
- Sandip Patel, Assistant Professor, Cancer Immunotherapy Program, University of California, San Diego
- Tony Pircher, Director of Immunochemistry, Biocept
- Elodie Sollier, Chief Scientific Officer, Vortex Biosciences
Cardiovascular Biomarkers - DISTINGUISHED SPEAKERS
- J. Brent Muhlestein, Co-Director of Cardiology Research, Intermountain Medical Center and Professor of Medicine, University of Utah
- John Nolan, Cellarcus Technologies, LLC
- Pei Pei Ping, Director, NIH BD2K Center of Excellence at UCLA; Professor, Medicine/Cardiology, and Bioinformatics, UCLA
- Jeffrey Price, Chief Executive Officer, Vala Sciences
- Rhonda Rhyne, Chief Executive Officer, Prevencio
- James Snider, President, Critical Diagnostics
- Jim Turk, Pathologist Director, Amgen
- Szilard Voros, Founder & Chief Executive Officer, Global Genomics Group
Inflammatory & Immunological Biomarkers - DISTINGUISHED SPEAKERS
- Mark Curran, Vice President, Immunology, Systems Pharmacology & Biomarkers, Janssen
- Andrew Holman, Chief Executive Officer & Co-founder, Inmedix Inc and Inmedix UK Ltd
- Morten Karsdal, Chief Executive Officer, Nordic Bioscience A/S
- Toshiaki Kawakami, Professor, Division of Cellular Biology, La Jolla Institute for Immunology & Allergy
- Calixte Monast, Senior Scientist, Janssen R&D
- Eric Sasso, Vice President, Medical & Scientific Affairs, Crescendo Bioscience
- Anuraag Shrivastav, Associate Professor, Department of Biology, University of Winnipeg
- Xuemei Zhao, Senior Principal Scientist, Merck
Neurological Biomarkers - DISTINGUISHED SPEAKERS
- Richard Batrla-Utermann, Medical Director, Roche
- Mark Frasier, Vice President, Research Programs, Michael J. Fox Foundation
- Arti Gaur, Assistant Professor of Neurology, Dartmouth Geisel School of Medicine
- Andreas Jeromin, Chief Medical Officer, Quanterix
- Stephen J. Kolb, Associate Professor, Department of Neurology and Biological Chemistry & Pharmacology; Director, Ohio State ALS/MND Multidisciplinary Clinic and Research Program, The Ohio State University Wexner Medical Center
- Christian Loch, Chief Executive & Science Officer, AVMBioMed
- Robert Rissman, Assistant Professor, University of California, San Diego
- Douglas Scharre, Director, Division of Cognitive Neurology, Department of Neurology, Ohio State University, Wexner Medical Centre
Please fill in your name and email to receive the conference agenda of this event.
The agenda is available as PDF under downloads at the right side of the page.
Venue
The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.
Venue
Omni San Diego Hotel675 L Street
San Diego, CA 92101
1-619-231-6664
